+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tumor Suppressor"

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2018 - Product Thumbnail Image

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2018

  • Drug Pipelines
  • September 2018
  • 150 Pages
  • Global
From
From
Drug Delivery in Cancer - Technologies, Markets & Companies - Product Thumbnail Image

Drug Delivery in Cancer - Technologies, Markets & Companies

  • Report
  • November 2021
  • 747 Pages
  • Global
From
From
Holland-Frei Cancer Medicine. Edition No. 10 - Product Thumbnail Image

Holland-Frei Cancer Medicine. Edition No. 10

  • Book
  • April 2023
  • 2000 Pages
Holland-Frei Cancer Medicine Cloth. Edition No. 9 - Product Thumbnail Image

Holland-Frei Cancer Medicine Cloth. Edition No. 9

  • Book
  • March 2017
  • 2008 Pages
Loading Indicator

Tumor suppressor drugs are a type of oncology drug used to treat cancer. They work by inhibiting the growth of cancer cells, either by blocking the growth of new cells or by killing existing cells. Tumor suppressors are typically used in combination with other treatments, such as chemotherapy or radiation therapy, to maximize the effectiveness of the treatment. They are also used to reduce the risk of recurrence of cancer after treatment. Tumor suppressors are typically administered orally or intravenously, depending on the type of cancer being treated. Common side effects of tumor suppressors include nausea, vomiting, fatigue, and hair loss. The tumor suppressor market is a rapidly growing segment of the oncology drug market. As the number of cancer cases continues to rise, the demand for effective treatments is increasing. This has led to an increase in research and development of new tumor suppressor drugs, as well as the development of new delivery methods. Some companies in the tumor suppressor market include Novartis, Merck, Pfizer, and AstraZeneca. Show Less Read more